8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
Mar 26, 2026·SEC
Rani Therapeutics Holdings, Inc.(RANI)Earnings, Financials & Key Ratios
RANI•NASDAQ
Price updated Jun 19, 2026
AboutRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.Show more
- Revenue$2M+58.9%
- EBITDA-$37M+28.5%
- Net Income-$30M+1.1%
- EPS (Diluted)-0.45+57.1%
- Gross Margin44.89%-55.1%
- EBITDA Margin-2290.88%+55.0%
- Operating Margin-2345.99%+54.8%
- Net Margin-1817.09%+37.8%
- ROE-131.87%+36.4%
RANI Key Insights
Rani Therapeutics Holdings, Inc. (RANI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 28.7%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Profits declining 12.2% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RANI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RANI Price & Volume
Rani Therapeutics Holdings, Inc. (RANI) stock price & volume — 10-year historical chart
Loading chart...
RANI Growth Metrics
Rani Therapeutics Holdings, Inc. (RANI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years28.73%
3 Years-
TTM164.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.68%
Return on Capital
10 Years-93.09%
5 Years-95.53%
3 Years-122.82%
Last Year-122.21%
RANI Recent Earnings
Rani Therapeutics Holdings, Inc. (RANI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.04+33.3%
$0.06
Rev
$2M+51.8%
$1M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.07-133.3%
$0.03
Rev
$1M-70.8%
$5M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.12-33.3%
$0.09
Rev
—
$5M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.18+5.3%
$0.19
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.04vs $0.06+33.3% | $2Mvs $1M+51.8% |
| Q2 2026 | Mar 26, 2026 | $0.07vs $0.03-133.3% | $1Mvs $5M-70.8% |
| Q4 2025 | Nov 6, 2025 | $0.12vs $0.09-33.3% | —vs $5M |
| Q3 2025 | Aug 7, 2025 | $0.18vs $0.19+5.3% | — |
Based on last 12 quarters of dataView full earnings history →
RANI Peer Comparison
Rani Therapeutics Holdings, Inc. (RANI) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 CDTX | 6.96B | 221.38 | -8.28 | -94.52% | -43.74% | 0.02 | ||
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare RANI vs Peers
Rani Therapeutics Holdings, Inc. (RANI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RANI Income Statement
Rani Therapeutics Holdings, Inc. (RANI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 979K | 462K | 2.72M | 0 | 0 | 1.03M | 1.63M | 3.17M |
Revenue Growth % | - | -52.81% | 488.1% | -100% | - | - | 58.85% | 164.08% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 822K | 0 | 900K | 161K |
COGS % of Revenue | - | - | - | - | - | - | 55.11% | - |
Gross Profit | 979K▲ 0% | 462K▼ 52.8% | 2.72M▲ 488.1% | 0▼ 100.0% | -822K▲ 0% | 1.03M▲ 225.1% | 733K▼ 28.7% | 3.01M▲ 0% |
Gross Margin % | 100% | 100% | 100% | - | - | 100% | 44.89% | 94.92% |
Gross Profit Growth % | - | -52.81% | 488.1% | -100% | - | 225.06% | -28.7% | - |
Operating Expenses | 28.04M | 17.01M | 54.32M | 63.45M | 65.28M | 54.34M | 39.04M | 37.64M |
OpEx % of Revenue | 2864.56% | 3680.95% | 1999.12% | - | - | 5286.19% | 2390.88% | - |
Selling, General & Admin | 3.46M | 4.96M | 27.83M | 26.84M | 26.48M | 23.95M | 19.74M | 19.01M |
SG&A % of Revenue | 353.93% | 1074.03% | 1024.44% | - | - | 2329.38% | 1208.7% | - |
Research & Development | 24.58M | 12.04M | 26.48M | 36.61M | 39.62M | 26.68M | 20.2M | 18.8M |
R&D % of Revenue | 2510.62% | 2606.93% | 974.68% | - | - | 2595.53% | 1237.29% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -822K | 3.71M | -900K | -161K |
Operating Income | -27.07M▲ 0% | -16.54M▲ 38.9% | -51.6M▼ 211.9% | -63.45M▼ 23.0% | -66.1M▼ 4.2% | -53.31M▲ 19.3% | -38.31M▲ 28.1% | -34.64M▲ 0% |
Operating Margin % | -2764.56% | -3580.95% | -1899.12% | - | - | -5186.19% | -2345.99% | -1092.96% |
Operating Income Growth % | - | 38.87% | -211.89% | -22.97% | -4.17% | 19.34% | 28.14% | - |
EBITDA | -26.5M | -15.96M | -51.1M | -62.9M | -65.28M | -52.29M | -37.41M | -33.83M |
EBITDA Margin % | -2706.95% | -3453.46% | -1880.82% | - | - | -5086.19% | -2290.88% | -1067.4% |
EBITDA Growth % | - | 39.79% | -220.29% | -23.09% | -3.77% | 19.9% | 28.45% | 32.7% |
D&A (Non-Cash Add-back) | 564K | 589K | 497K | 548K | 822K | 1.03M | 900K | 810K |
EBIT | -26.58M | -16.54M | -52.58M | -62.2M | -66.1M | -51.55M | -38.31M | -34.6M |
Net Interest Income | 413K | -61K | -377K | 177K | -1.78M | -3.27M | -2.06M | -1.01M |
Interest Income | 423K | 63K | 89K | 1.25M | 3.3M | 1.76M | 827K | 1.02M |
Interest Expense | 10K | 124K | 466K | 1.07M | 5.08M | 5.03M | 2.89M | 2.04M |
Other Income/Expense | 478K | -124K | -1.45M | 177K | -1.78M | 23.3M | -2.64M | -1.59M |
Pretax Income | -26.59M▲ 0% | -16.67M▲ 37.3% | -53.05M▼ 218.3% | -63.27M▼ 19.3% | -67.88M▼ 7.3% | -30.02M▲ 55.8% | -40.95M▼ 36.4% | -36.23M▲ 0% |
Pretax Margin % | -2715.73% | -3607.79% | -1952.41% | - | - | -2920.04% | -2507.65% | -1143.17% |
Income Tax | 0 | 35K | 41K | 70K | 0 | 26.57M | 0 | 0 |
Effective Tax Rate % | 0% | -0.21% | -0.08% | -0.11% | 0% | -88.5% | 0% | 0% |
Net Income | -26.6M▲ 0% | -16.7M▲ 37.2% | -8.33M▲ 50.1% | -30.59M▼ 267.2% | -33.97M▼ 11.1% | -30.02M▲ 11.6% | -29.67M▲ 1.1% | -29.44M▲ 0% |
Net Margin % | -2716.75% | -3615.37% | -306.63% | - | - | -2920.04% | -1817.09% | -929.06% |
Net Income Growth % | - | 37.2% | 50.12% | -267.16% | -11.06% | 11.63% | 1.15% | 1.2% |
Net Income (Continuing) | -26.59M | -16.7M | -53.09M | -63.34M | -67.88M | -56.58M | -40.95M | -36.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 74.16M | 37.15M | 12.58M | 1.5M | 8.5M | 7.14M |
EPS (Diluted) | -1.35▲ 0% | -0.85▲ 37.0% | -0.42▲ 50.6% | -1.28▼ 204.8% | -1.33▼ 3.9% | -1.05▲ 21.1% | -0.45▲ 57.1% | -0.16▲ 0% |
EPS Growth % | - | 37.04% | 50.59% | -204.76% | -3.91% | 21.05% | 57.14% | 58.68% |
EPS (Basic) | -1.35 | -0.85 | -0.42 | -1.28 | -1.33 | -1.05 | -0.45 | - |
Diluted Shares Outstanding | 18.74M | 18.74M | 19.53M | 23.82M | 25.5M | 28.48M | 66.14M | 180M |
Basic Shares Outstanding | 18.74M | 18.74M | 19.53M | 23.82M | 25.5M | 28.48M | 66.14M | 180M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RANI Balance Sheet
Rani Therapeutics Holdings, Inc. (RANI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 16.94M | 74.94M | 119.59M | 100.92M | 50.85M | 29.74M | 53.32M | 47.09M |
Cash & Short-Term Investments | 16.54M | 73.06M | 117.45M | 98.48M | 48.54M | 27.64M | 49.71M | 43.4M |
Cash Only | 16.54M | 73.06M | 117.45M | 27.01M | 5.86M | 3.76M | 18.62M | 9.64M |
Short-Term Investments | 0 | 0 | 0 | 71.47M | 42.67M | 23.88M | 31.09M | 33.76M |
Accounts Receivable | 250K | 1.72M | 0 | 0 | 200K | 428K | 2.04M | 2.11M |
Days Sales Outstanding | 93.21 | 1.36K | - | - | - | 151.97 | 456.42 | 119.64 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 500K | 800K | 1.68M | 1.57M | 1.57M |
Total Non-Current Assets | 6.08M | 4.47M | 4.61M | 7.1M | 7.07M | 6.89M | 5.3M | 4.79M |
Property, Plant & Equipment | 4.45M | 4.47M | 4.61M | 7.1M | 6.82M | 6.64M | 5.05M | 4.54M |
Fixed Asset Turnover | 0.22x | 0.10x | 0.59x | - | - | 0.15x | 0.32x | 0.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 246K | 246K | 246K | 246K |
Total Assets | 23.02M▲ 0% | 79.42M▲ 245.0% | 124.21M▲ 56.4% | 108.03M▼ 13.0% | 57.92M▼ 46.4% | 36.63M▼ 36.7% | 58.62M▲ 60.0% | 51.88M▲ 0% |
Asset Turnover | 0.04x | 0.01x | 0.02x | - | - | 0.03x | 0.03x | 0.09x |
Asset Growth % | - | 244.95% | 56.4% | -13.03% | -46.39% | -36.75% | 60.02% | 36.99% |
Total Current Liabilities | 3.5M | 5.31M | 2.64M | 4.82M | 7.99M | 19.89M | 12.67M | 13.86M |
Accounts Payable | 198K | 537K | 1.08M | 1.46M | 648K | 1.36M | 309K | 858K |
Days Payables Outstanding | - | - | - | - | 287.74 | - | 125.32 | 3.08K |
Short-Term Debt | 0 | 1.36M | 0 | 0 | 4.9M | 15M | 1.59M | 1.46M |
Deferred Revenue (Current) | 179K | 2.72M | 0 | 0 | 1.21M | 0 | 6.83M | 13.66M |
Other Current Liabilities | 601K | 88K | 126K | 591K | 202K | 283K | 3.94M | 4.71M |
Current Ratio | 4.84x | 14.12x | 45.30x | 20.96x | 6.36x | 1.50x | 4.21x | 3.40x |
Quick Ratio | 4.84x | 14.12x | 45.30x | 20.96x | 6.36x | 1.50x | 4.21x | 3.40x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -2.96K |
Total Non-Current Liabilities | 116.16M | 187.45M | 0 | 29.21M | 24.48M | 13.25M | 4.44M | 2.48M |
Long-Term Debt | 115.5M | 2.41M | 0 | 29.15M | 24.48M | 9.61M | 2.73M | 2.48M |
Capital Lease Obligations | 0 | 0 | 0 | 59K | 0 | 3.64M | 0 | 3.2M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 655K | 185.03M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 119.66M | 192.75M | 2.64M | 34.02M | 32.47M | 33.14M | 17.11M | 16.34M |
Total Debt | 115.5M | 3.77M | 0 | 30.21M | 30.1M | 29.71M | 4.32M | 3.94M |
Net Debt | 98.97M | -69.29M | -117.45M | 3.21M | 24.23M | 25.95M | -14.3M | -5.7M |
Debt / Equity | - | - | - | 0.41x | 1.18x | 8.51x | 0.10x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.12x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.17x |
Interest Coverage | -2657.70x | -133.42x | -112.83x | -58.08x | -13.00x | -10.24x | -13.25x | -16.99x |
Total Equity | -96.64M▲ 0% | -113.34M▼ 17.3% | 121.57M▲ 207.3% | 74M▼ 39.1% | 25.44M▼ 65.6% | 3.49M▼ 86.3% | 41.51M▲ 1088.4% | 35.54M▲ 0% |
Equity Growth % | - | -17.28% | 207.26% | -39.12% | -65.62% | -86.27% | 1088.43% | 1280.67% |
Book Value per Share | -5.16 | -6.05 | 6.22 | 3.11 | 1.00 | 0.12 | 0.63 | 0.20 |
Total Shareholders' Equity | -96.64M | -113.34M | 47.41M | 36.85M | 12.87M | 1.99M | 33.01M | 28.41M |
Common Stock | 664K | 664K | 5K | 5K | 5K | 5K | 11K | 11K |
Retained Earnings | -97.3M | -114M | -8.33M | -38.92M | -72.89M | -102.91M | -132.58M | -139.61M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -780.16K | -849.03K | 0 | -73K | -12K | 5K | 0 | -8K |
Minority Interest | 0 | 0 | 74.16M | 37.15M | 12.58M | 1.5M | 8.5M | 7.14M |
RANI Cash Flow Statement
Rani Therapeutics Holdings, Inc. (RANI) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -26.27M | -14.96M | -32.24M | -46.52M | -51.24M | -35.5M | -18.71M | -17.06M |
Operating CF Margin % | -2683.04% | -3238.1% | -1186.79% | - | - | -3452.92% | -1145.99% | - |
Operating CF Growth % | - | 43.05% | -115.54% | -44.25% | -10.15% | 30.72% | 47.28% | 199.27% |
Net Income | -26.59M | -16.7M | -8.33M | -63.34M | -33.97M | -56.58M | -29.67M | -29.44M |
Depreciation & Amortization | 564K | 589K | 497K | 548K | 822K | 1.03M | 900K | 810K |
Stock-Based Compensation | 0 | 0 | 22.59M | 15.78M | 19.01M | 16.03M | 11.8M | 6.67M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -81K | 110K | -43.58M | -10K | -34.96M | 4.57M | -8.7M | 1.19M |
Working Capital Changes | -163K | 1.04M | -3.43M | 509K | -2.14M | -544K | 6.96M | 5.97M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -428K | -1.61M | -1.01M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -271K | 933K | 543K | 163K | -595K | 711K | -1.05M | -662K |
Cash from Investing | -1.53M | -1.2M | -506K | -72.44M | 29.86M | 19.81M | -7.03M | -27.71M |
Capital Expenditures | -1.58M | -1.2M | -506K | -1.62M | -1.23M | -268K | -88K | -52K |
CapEx % of Revenue | 161.49% | 259.74% | 18.62% | - | - | 26.07% | 5.39% | 1.64% |
Acquisitions | 49K | 0 | 0 | -851K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 851K | 0 | 1.25M | 278K | 244K |
Cash from Financing | 852K | 72.68M | 77.15M | 29M | 233K | 13.59M | 40.3M | 44M |
Debt Issued (Net) | 0 | 4.19M | -2.85M | 29.57M | 0 | -5M | -20.72M | -16.97M |
Equity Issued (Net) | 0 | 71.27M | 79.97M | 317K | 395K | 18.63M | 61.08M | 58.23M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 852K | -2.78M | 26K | -886K | -162K | -47K | -59K | 2.74M |
Net Change in Cash | -26.95M▲ 0% | 56.52M▲ 309.8% | 44.4M▼ 21.5% | -89.95M▼ 302.6% | -21.14M▲ 76.5% | -2.1M▲ 90.1% | 14.56M▲ 792.5% | -767K▲ 0% |
Free Cash Flow | -27.85M▲ 0% | -16.16M▲ 42.0% | -32.75M▼ 102.7% | -48.13M▼ 47.0% | -52.47M▼ 9.0% | -35.76M▲ 31.8% | -18.8M▲ 47.4% | -17.11M▲ 0% |
FCF Margin % | -2844.54% | -3497.84% | -1205.41% | - | - | -3478.99% | -1151.38% | -540.04% |
FCF Growth % | - | 41.97% | -102.67% | -46.97% | -9% | 31.83% | 47.43% | 50.46% |
FCF per Share | -1.49 | -0.86 | -1.68 | -2.02 | -2.06 | -1.26 | -0.28 | -0.10 |
FCF Conversion (FCF/Net Income) | 0.99x | 0.90x | 3.87x | 1.52x | 1.51x | 1.18x | 0.63x | 0.58x |
Interest Paid | 0 | 0 | 285K | 730K | 4.18M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 73K | 48K | 35K | 0 | 0 | 0 |
RANI Key Ratios
Rani Therapeutics Holdings, Inc. (RANI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -202.5% | -31.28% | -68.32% | -207.48% | -131.87% | -210.57% |
Return on Invested Capital (ROIC) | - | -940.67% | -117.03% | -78.14% | -101.08% | -101.44% | -171.08% |
Gross Margin | 100% | 100% | - | - | 100% | 44.89% | 94.92% |
Net Margin | -3615.37% | -306.63% | - | - | -2920.04% | -1817.09% | -929.06% |
Debt / Equity | - | - | 0.41x | 1.18x | 8.51x | 0.10x | 0.11x |
Interest Coverage | -133.42x | -112.83x | -58.08x | -13.00x | -10.24x | -13.25x | -16.99x |
FCF Conversion | 0.90x | 3.87x | 1.52x | 1.51x | 1.18x | 0.63x | 0.58x |
Revenue Growth | -52.81% | 488.1% | -100% | - | - | 58.85% | 164.08% |
Related:RANI Dividend History·RANI Revenue History·RANI Price History·RANI P/E History·RANI Financial Ratios·RANI Institutional Holders
RANI SEC Filings & Documents
Rani Therapeutics Holdings, Inc. (RANI) SEC filings — annual & quarterly reports (10-K, 10-Q)
RANI Frequently Asked Questions
Rani Therapeutics Holdings, Inc. (RANI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rani Therapeutics Holdings, Inc. (RANI) reported $3.2M in revenue for fiscal year 2025. This represents a 224% increase from $1.0M in 2019.
Rani Therapeutics Holdings, Inc. (RANI) grew revenue by 58.9% over the past year. This is strong growth.
Rani Therapeutics Holdings, Inc. (RANI) reported a net loss of $29.4M for fiscal year 2025.
Dividend & Returns
Rani Therapeutics Holdings, Inc. (RANI) has a return on equity (ROE) of -131.9%. Negative ROE indicates the company is unprofitable.
Rani Therapeutics Holdings, Inc. (RANI) had negative free cash flow of $17.1M in fiscal year 2025, likely due to heavy capital investments.